A New Family of Cancer-Targeting Compounds Permanently Switches Off a Tumor's Built-In Defense System
A Team of Russian scientists have successfully developed a new series of oxazol-5(4H)-one derivatives that function as potent and selective TrxR1 inhibitors. Led by Dr. Evgeny Chupakhin at Immanuel Kant Baltic Federal University in Kaliningrad the team used rational drug design to identify and synthesize the new compounds.
The Target: An Enzyme That Helps Cancer Cells Survive
Cancer cells are remarkably good at protecting themselves from the very treatments designed to kill them. One of the key tools they use is an enzyme called thioredoxin reductase 1 (TrxR1), which sits at the heart of their antioxidant defence network. By neutralizing the damaging molecules that build up inside a tumor — including the toxic byproducts generated by chemotherapy and radiotherapy — TrxR1 helps cancer cells survive conditions that should destroy them. Blocking this enzyme has therefore become an important goal in cancer drug development. A new study published in The Open Medicinal Chemistry Journal by researchers at Immanuel Kant Baltic Federal University in Kaliningrad, Russia, reports the design, synthesis, and laboratory testing of 18 new compounds from a chemical family called oxazol-5(4H)-ones — compact, drug-like molecules that had not previously been explored as TrxR1 inhibitors. The work was financially supported by the Russian Science Fund (grant number 24-23-00603).
What the Compounds Do — and How Three of Them Stood Out
The research team began by screening a commercial library of existing oxazolones and identifying two compounds that suppressed TrxR1 activity by more than 20% at low concentrations. Using this as a starting point, they built a computational model of how these molecules fit into the enzyme's active site — specifically targeting a rare and reactive amino acid called selenocysteine that sits at TrxR1's core — and then used those insights to design and synthesise 18 new variants. When tested in laboratory assays on human lung cancer cell extracts, three compounds — labelled 1i, 1o, and 1s — stood out clearly. All three suppressed TrxR1 activity by more than 50%, and their half-maximal inhibitory concentrations (IC50) were measured in the nanomolar range: 0.25 nM for compound 1i, 4.2 nM for 1s, and 19.7 nM for 1o. Crucially, all three showed far weaker activity against glutathione reductase — a structurally similar enzyme found in healthy cells — indicating that they preferentially target TrxR1 rather than disrupting other parts of the cell's chemistry indiscriminately. In cancer cell toxicity tests across five cell lines — lung carcinoma, neuroblastoma, glioblastoma, cervical cancer, and normal kidney cells — compound 1i was most potent against glioblastoma cells (IC50 = 12.58 µM) while being considerably less toxic to healthy cells, giving it a therapeutic selectivity index of 4.12. Compound 1o showed its strongest and most selective effect against neuroblastoma cells. The team also made an unexpected mechanistic discovery: a subset of the compounds — those carrying two reactive chemical handles rather than one — caused TrxR1 molecules to physically crosslink with each other, forming stable dimers that could be clearly detected by protein analysis. This crosslinking permanently locks the enzyme in an inactivated state, a mechanism distinct from conventional inhibition and one with significant implications for how these compounds could be developed further.
What This Means for Future Cancer Drug Development
The findings establish oxazolone-based compounds as a promising new direction for anticancer drug research focused on the thioredoxin system. Their compact structure, compliance with standard drug-likeness criteria, and ability to be chemically varied in many ways make them well-suited for further refinement. The discovery of TrxR1 dimerisation — a form of permanent, irreversible enzyme inactivation — adds a novel mechanism to the toolkit of covalent drug design and opens a new avenue for designing compounds that can shut down the thioredoxin system in a way that cancer cells cannot easily reverse. The authors acknowledge the study's limitations: all experiments were conducted in cell culture rather than in living animals, the cancer cell panel was small, and the long-term safety profile and behaviour of these compounds in the body have not yet been assessed. One puzzling finding — that compound 1s showed strong toxicity in glioblastoma cells that appeared to lack detectable TrxR1 expression — also warrants further investigation to determine whether alternative mechanisms are at play.
Read the published article here: https://bit.ly/3SP45v7
JOURNAL
The Open Medicinal Chemistry Journal:
DOI: 10.2174/0118741045455822260514110908
If you want to publish your article please visit : https://bit.ly/4de0DRi
The Open Medicinal Chemistry Journal
10.2174/0118741045455822260514110908
Covalent Inhibition of Thioredoxin Reductase by Michael Acceptors: Rational Design, Synthesis, and Biological Evaluation of Oxazol-5(4H)-one Derivatives